Therapy-Resistant Acute Myeloid Leukemia Stem Cells Are Resensitized to Venetoclax + Azacitidine by Targeting Fatty Acid Desaturases 1 and 2

Recent advances in targeting leukemic stem cells (LSCs) using venetoclax with azacitidine (ven + aza) has significantly improved outcomes for de novo acute myeloid leukemia (AML) patients. However, patients who relapse after traditional chemotherapy are often venetoclax-resistant and exhibit poor cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Culp-Hill, Rachel, Stevens, Brett M., Jones, Courtney L., Pei, Shanshan, Dzieciatkowska, Monika, Minhajuddin, Mohammad, Jordan, Craig T., D’Alessandro, Angelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142983/
https://www.ncbi.nlm.nih.gov/pubmed/37110126
http://dx.doi.org/10.3390/metabo13040467

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142983/
https://www.ncbi.nlm.nih.gov/pubmed/37110126
http://dx.doi.org/10.3390/metabo13040467

Ejemplares similares